Collaborations & Alliances

Absci, AstraZeneca Enter AI-Driven Oncology Alliance

Will leverage Absci's Drug Creation platform with the goal of accelerating the discovery of a potential new cancer treatment candidate.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Absci Corp., a generative AI antibody discovery firm, entered a collaboration with AstraZeneca to deliver an AI-designed antibody against an oncology target. The collaboration will leverage Absci’s Integrated Drug Creation platform and AstraZeneca’s expertise in oncology with the goal of accelerating the discovery of a potential new cancer treatment candidate.   Absci will contribute generative AI technology to deliver a therapeutic candidate antibody for a specified oncology targe...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters